A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT ID: NCT01740336
Last Updated: 2017-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
183 participants
INTERVENTIONAL
2013-02-06
2015-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
NCT00320541
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01254526
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
NCT00006120
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT00960960
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
NCT00635050
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A: Paclitaxel, GDC-0941
Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m\^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
GDC-0941
GDC-0941 will be administered QD orally for 5 consecutive days each week.
Paclitaxel
Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
B: Paclitaxel, Placebo
Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m\^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
Placebo
Placebo matching to GDC-0941
Paclitaxel
Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GDC-0941
GDC-0941 will be administered QD orally for 5 consecutive days each week.
Placebo
Placebo matching to GDC-0941
Paclitaxel
Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Human epidermal growth factor receptor 2 (HER2)-negative and hormone receptor (HR) (estrogen receptor and/or progesterone receptor)-positive disease as defined by local guidelines
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate hematologic and end organ function
* Women of childbearing potential must agree to remain abstinent or to use two adequate methods of contraception, including at least one method with a failure rate of less than (\<) 1 percent (%) per year, during the treatment period and for at least 30 days after the last dose of study treatment or 6 months after discontinuation of paclitaxel, whichever is longer
Exclusion Criteria
* Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor for advanced or metastatic breast cancer
* History of intolerance to a taxane-containing therapy
* History of clinically significant cardiac or pulmonary dysfunction
* History of malabsorption syndrome or other condition that would interfere with enteral absorption
* Clinically significant history of liver disease
* Active autoimmune disease or active inflammatory disease
* Immunocompromised status due to current known active infection with human immunodeficiency virus (HIV) or due to the use of immunosuppressive therapies for other conditions
* Need for current chronic corticosteroid therapy
* Pregnant, lactating, or breastfeeding women
* Current severe, uncontrolled systemic disease
* Known untreated or active central nervous system (CNS) metastases
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Genentech, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Oncology Associates, PC - NAHOA
Sedona, Arizona, United States
Pacific Cancer Medical Center
Anaheim, California, United States
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California, United States
Kaiser Permanente - Hayward
Hayward, California, United States
Kaiser Permanente - Oakland
Oakland, California, United States
Bay Area Cancer Research Group, LLC
Pleasant Hill, California, United States
Kaiser Permanente Medical Center - Roseville
Roseville, California, United States
Kaiser Permanente Sacramento Medical Center
Sacramento, California, United States
Kaiser Permanente - San Francisco (2238 Geary)
San Francisco, California, United States
University of California at San Francisco
San Francisco, California, United States
Kaiser Permanente - San Jose
San Jose, California, United States
Kaiser Permanente - Santa Clara
Santa Clara, California, United States
Kaiser Permanente - South San Francisco
South San Francisco, California, United States
Kaiser Permanente - Vallejo
Vallejo, California, United States
Kaiser Permanente - Walnut Creek
Walnut Creek, California, United States
Helen & Harry Gray Cancer Center-Hartford Hospital-CCD PRIME; Research
Hartford, Connecticut, United States
Clinical Research of South Florida
Coral Gables, Florida, United States
Cancer Specialists of North Florida
Orange Park, Florida, United States
Hematology - Oncology Associates of Treasure Coast
Port Saint Lucie, Florida, United States
Phoebe Putney Memorial Hospital
Albany, Georgia, United States
Joliet Oncology-Hematology; Associates, Ltd.
Joliet, Illinois, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Cotton-O'Neil Clinical Research Center, Hematology and Oncology; Cotton O'Neil Cancer Center
Topeka, Kansas, United States
Hematology Oncology Clinic
Baton Rouge, Louisiana, United States
Metairie Oncologist, LLC
Metairie, Louisiana, United States
Maine Research Associates
Auburn, Maine, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Beth Israel Deaconess Med Ctr
Brookline, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Billings Clinic Cancer Center-CCD PRIME
Billings, Missouri, United States
Nebraska Cancer Specialists; Oncology Hematology West, PC
Omaha, Nebraska, United States
ProHEALTH Care Associates LLP
Lake Success, New York, United States
Summa Health System
Akron, Ohio, United States
Aultman Hospital; Aultman Hospital Cancer Center
Canton, Ohio, United States
TriHealth Oncology Institute
Cincinnati, Ohio, United States
Abington Memorial Hospital
Abington, Pennsylvania, United States
Hematology and Oncology Associates of Sc
Greenville, South Carolina, United States
Shivers Cancer Center at University Medical Center Brackenridge
Austin, Texas, United States
Texas Oncology
Bedford, Texas, United States
Texas Oncology, P.A. - El Paso; West
El Paso, Texas, United States
Texas Oncology - Memorial City
Houston, Texas, United States
Texas Oncology, P.A. ;Sherman Cancer Center
Sherman, Texas, United States
Northern Utah Associates
Ogden, Utah, United States
Shenandoah Oncology Associates
Winchester, Virginia, United States
Puget Sound Cancer Centers
Edmonds, Washington, United States
Swedish Health Services
Seattle, Washington, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Port Macquarie Base Hospital;North Coast Cancer Institute
Port Macquarie, New South Wales, Australia
Sydney Haematology & Oncology Clinic
Wahroonga, New South Wales, Australia
Calvary Mater Newcastle; Medical Oncology
Waratah, New South Wales, Australia
Border Medical Oncology
Wodonga, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Mater Adult Hospital
Mackay, Queensland, Australia
Ashford Cancer Center Research
Kurralta Park, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Bendigo Hospital; Oncology
Bendigo, Victoria, Australia
Peninsula and South Eastern Haematology and Oncology Grou
Frankston, Victoria, Australia
Royal Perth Hospital; Medical Oncology
Perth, Western Australia, Australia
Lkh-Univ. Klinikum Graz
Graz, , Austria
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, , Austria
Krankenhaus Hietzing m.Neurolog. Zentrum Rosenhuegel
Vienna, , Austria
Klinikum Wels-Grieskirchen
Wels, , Austria
Institut Jules Bordet
Brussels, , Belgium
UZ Antwerpen
Edegem, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
CHU Ambroise Paré
Mons, , Belgium
Clinique Ste-Elisabeth
Namur, , Belgium
Sint Augustinus Wilrijk
Wilrijk, , Belgium
Fakultni nemocnice Brno
Brno, , Czechia
Masarykuv onkologicky ustav
Brno, , Czechia
Krajska nemocnice Liberec a.s.
Liberec, , Czechia
Multiscan s.r.o.
Pardubice, , Czechia
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Nemocnice Na Bulovce
Prague, , Czechia
Thomayerova nemocnice
Praha 4 - Krc, , Czechia
Chungbuk National University Hospital
Cheongju-si, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Institut Catala d´Oncologia Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Institut Catala d Oncologia Hospital Duran i Reynals
Barcelona, , Spain
Complejo Hospitalario de Jaen
Jaén, , Spain
Hospital General Univ. Gregorio Maranon
Madrid, , Spain
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
Madrid, , Spain
Royal Sussex County Hospital
Brighton, , United Kingdom
Royal Surrey County Hospital
Guildford, , United Kingdom
Leicester Royal Infirmary
Leicester, , United Kingdom
Barts Hospital
London, , United Kingdom
The Christie
Manchester, , United Kingdom
Freeman Hospital
Newcastle upon Tyne, , United Kingdom
Nottingham University Hospitals City Campus
Nottingham, , United Kingdom
Royal Stoke University Hospital
Stoke-on-Trent, , United Kingdom
Royal Cornwall Hospital
Truro, , United Kingdom
New Cross Hospital
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vuylsteke P, Huizing M, Petrakova K, Roylance R, Laing R, Chan S, Abell F, Gendreau S, Rooney I, Apt D, Zhou J, Singel S, Fehrenbacher L. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann Oncol. 2016 Nov;27(11):2059-2066. doi: 10.1093/annonc/mdw320. Epub 2016 Aug 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-003262-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GO28509
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.